Acadia Pharmaceuticals (ACAD) Revenue (2010 - 2026)

Acadia Pharmaceuticals' Revenue history runs 17 years deep, the most recent figure standing at $268.1 million for Q1 2026.

• On a quarterly basis, Revenue rose 9.72% year-over-year to $268.1 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 9.93% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 11.87% from the prior year.
• Revenue slipped to $268.1 million in Q1 2026 per ACAD's latest filing, from $284.0 million in the prior quarter.
• Across five years, Revenue topped out at $284.0 million in Q4 2025 and bottomed at $115.5 million in Q1 2022.
• The 5-year median for Revenue is $231.0 million (2023), against an average of $208.3 million.
• Across the five-year window, Revenue dropped 0.68% in 2022 and jumped 73.75% in 2024, its largest moves.
• Year by year, Revenue stood at $136.5 million in 2022, then soared by 69.27% to $231.0 million in 2023, then rose by 12.36% to $259.6 million in 2024, then increased by 9.39% to $284.0 million in 2025, then declined by 5.61% to $268.1 million in 2026.
• Per Business Quant, the three latest ACAD Revenue figures stand at $268.1 million (Q1 2026), $284.0 million (Q4 2025), and $278.6 million (Q3 2025).